Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
May 08, 2026
iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

Key Takeaways

  • IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures.
  • Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.
  • Top holdings like ISRG and EW contributed significantly to the downside, while gains in ABT and SYK provided limited offset.
  • Higher interest rates and sector rotation away from growth-oriented healthcare stocks weighed on performance.
  • Fund flows showed net outflows over the past year, reflecting reduced investor interest in the niche medical devices theme.

Understanding IHI and Its Portfolio Focus

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, offering targeted exposure to U.S. companies that manufacture and distribute medical devices, including imaging equipment, prosthetics, and surgical tools. It holds about 52 stocks, with the top 10 making up over 75% of assets. Key positions include ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is entirely allocated to healthcare, zeroing in on the medical devices subsector. This focus makes IHI particularly sensitive to industry challenges like reduced hospital spending and procedural delays, which has amplified its recent declines relative to more diversified healthcare ETFs.

IHI's Recent Price Action: 30 Days and Quarterly View

In the last 30 days, IHI fell from around $54.35 to $49.77, marking a -8.5% decline. The path was volatile and downward-trending, with sharp drops in late April speeding up the selloff. Over the past quarter, the retreat was even steeper at -15% from near $58.50 levels, driven by steady erosion amid broader market shifts. These moves line up with trailing returns of -4.3% for the prior month and -14.9% for three months as of early May, pointing to a bearish, range-bound pattern with lower highs. From what I see, this confirms ongoing pressure in the space.

Key Drivers Behind IHI's 30-Day Decline

The ETF's downturn over the past 30 days came mainly from weakness in its largest holdings and sector headwinds. Top holding ISRG dropped over 2%, pulling IHI lower given its 16.5% weight, while EW (Edwards Lifesciences) slid on concerns about cardiac device demand. Gains in ABT (up significantly) and SYK offered some cushion, but the portfolio's concentration magnified the losses. Softer demand for implants and neurotechnology—evident in Stryker's Q1 earnings miss—added to the strain. On the macro side, high interest rates raised financing costs for growth-reliant medtech companies, spurring profit-taking. Net fund outflows and a shift in sentiment toward value sectors only intensified the pressure. I also checked this using Tickeron’s AI Screener to gauge how IHI stacks up against peers.

Factors Shaping IHI's Quarterly Performance

The -15% quarterly slide built from mounting pressures on medical devices, including stretched valuations after 2025 gains and tighter macro conditions. Holdings like ISRG and EW lagged due to slower procedural growth and supply chain hurdles, while higher rates discounted future cash flows for innovation-focused firms. Earnings from peers like Stryker showed weaker demand in orthopedics and surgery, diverging from broader healthcare strength. Institutional outflows reached hundreds of millions over the year, with assets under management shrinking from $3.5B+ peaks, signaling fading confidence. Longer-term issues like hospital budget limits and rotation to cyclicals deepened the underperformance against health benchmarks. One thing that stands out is how these dynamics have persisted.

Why I Rely on Tickeron’s AI Screener for ETF Analysis

In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and performance metrics, surfacing trade ideas, breakouts, and opportunities faster than manual methods. This has been invaluable for tracking sector performance and dynamic ETF moves like those in medical devices. I’m watching it closely for the next insights.

Looking Ahead for IHI: Key Factors to Monitor

Looking forward, keep an eye on demand signals in medical devices, such as hospital procedure volumes and Q2 earnings from leaders like SYK and ISRG. The macro backdrop—Federal Reserve rate decisions and inflation—will shape valuations for growth names. Major holdings' progress in areas like robotic surgery adoption matters too. Supply chain stability and regulatory shifts could also influence the ETF. Risks persist from extended weak demand or outflows, but improved flows or rate cuts might aid a rebound. This is important because it frames the potential path.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: IHI

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for IHI turns positive, indicating new upward trend

IHI saw its Momentum Indicator move above the 0 level on July 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IHI just turned positive on July 28, 2026. Looking at past instances where IHI's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

IHI moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IHI advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 285 cases where IHI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IHI broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC. The index includes medical equipment companies, including manufacturers and distributors of medical devices such as magnetic resonance imaging scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares US Medical Devices ETF ETF is 23.7B. The market cap for tickers in the group ranges from 288.75M to 194.98B. ABT holds the highest valuation in this group at 194.98B. The lowest valued company is TMCI at 288.75M.

High and low price notable news

The average weekly price growth across all stocks in the iShares US Medical Devices ETF ETF was 10%. For the same ETF, the average monthly price growth was 75%, and the average quarterly price growth was 194%. AORT experienced the highest price growth at 8%, while IDXX experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the iShares US Medical Devices ETF ETF was -27%. For the same stocks of the ETF, the average monthly volume growth was -28% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 63
Price Growth Rating: 44
SMR Rating: 76
Profit Risk Rating: 89
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
IHI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Q4 2025 revenue reached $12.5 billion, exceeding expectations, with growth portfolio sales up 16% year-over-year. Full-year 2025 revenue totaled $48.2 billion, supported by Eliquis, Opdivo, and newer products including Breyanzi and Camzyos.
KKR reported Q4 2025 adjusted EPS of $1.12, slightly below the $1.14 consensus estimate. The firm raised a record $129 billion in 2025, surpassing 80% of its $300 billion fundraising goal for 2024–2026.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Barrick delivered record Q4 and full-year 2025 results, reporting $6 billion in Q4 revenue and full-year EPS of $2.93, ahead of expectations.
Smoke-free products accounted for 41.5% of total net revenues in 2025, with shipment volumes rising 12.8%.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.